Compositions favoring wound repair
OwnerSylvain Guerin, Lucie Germain +3inventors
InventorsSylvain Guerin, Lucie Germain, Karine Zaniolo, Camille Couture, Pascale Desjardins
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of favouring epithelial wound healing in a subject. Wounds suitable for this method include wounds located on the skin or in a cornea The methods comprise contacting a wound with an activator of an AKT pathway and/or an inhibitor of the MAPK pathway such as CREB inhibitors. Preferred compounds include SC-79, C646, curcumin, platelet-derived growth factor, 4′chloro-3-hydroxy-2-naphthanilide and fumonisin B. A model for wound healing is also disclosed. The model can be used to identify test compounds that are AKT activators or inhibitors of MAPK pathway, which are suitable to favoring epithelial wound healing.
Claims10
A method of favoring healing of an epithelial wound located in a cornea of a subject, said method comprising contacting a wound healing efficient amount of a pharmaceutical composition with the corneal epithelial wound, wherein the pharmaceutical composition comprises (i) SC-79 and (ii) C646 in combination with a pharmaceutically acceptable carrier.
A method for determining the usefulness of a test compound to favor wound healing of a corneal epithelial wound, said method comprising:
- (a) contacting the test compound with a first corneal epithelial cell to obtain a treated corneal epithelial cell;
- (b) determining, in the treated corneal epithelial cell, if the test compound activates the AKT pathway and inhibits the MAPK pathway;
- and
- (c) characterizing the test compound as useful for favoring wound healing of the corneal epithelial wound when it is determined that the test compound activates, in the treated corneal epithelial cell, the AKT pathway and inhibits, in the treated epithelial cell, the MAPK pathway.
Dependencies are inferred from the claim text.